Shire plots an ADHD public spinoff as CEO Ornskov completes a top-to-bottom overhaul
Hard on the heels of winning an approval for its long-lasting version of Adderall for ADHD, Shire says it’s now considering spinning off its blockbuster franchise drugs in that field into a new public company, marking a final restructuring that will leave the Boston-based biotech focused on rare diseases.
Shire said in its Q2 statement Thursday morning that the company has been doing a strategic review of its neurosciences division, considering its options on how best to handle the franchise, and says that a public listing is one big option. Shire’s stock $SHPG jumped more than 3% on the news.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.